State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
J Exp Clin Cancer Res. 2019 Jul 24;38(1):329. doi: 10.1186/s13046-019-1331-8.
Kinesins play important roles in the development and progression of many human cancers. The functions and underlying mechanisms of kinesin family member C1 (KIFC1), a member of the kinesin-14 family, in the pathogenesis of hepatocellular carcinoma (HCC) have not been fully elucidated.
In this study, 168 HCC samples were first analyzed to examine the association between KIFC1 expression and patient clinicopathological features and prognosis. The role of KIFC1 in HCC cell proliferation and metastasis was investigated both in vivo and in vitro. The upstream regulation and downstream targets of KIFC1 were studied by qRT-PCR, western blotting, coimmunoprecipitation, chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays.
KIFC1 was highly expressed in HCC tissues and positively associated with advanced stages and poor prognosis. KIFC1 knockdown suppressed HCC cell proliferation and invasion both in vitro and in vivo. Furthermore, KIFC1 knockdown decreased invadopodia formation and reduced epithelial-mesenchymal transition (EMT). HMGA1, an architectural transcriptional factor, was identified to interact with KIFC1. HMGA1 could bind to the promoters of Stat3, MMP2 and EMT-related genes and promote gene transcription. KIFC1 enhanced HMGA1 transcriptional activity and facilitated HCC proliferation and invasion. Moreover, KIFC1 was activated by TCF-4, and KIFC1 inhibition enhanced HCC cell sensitivity to paclitaxel.
Our findings suggest that KIFC1, activated by TCF-4, functions as an oncogene and promotes HCC pathogenesis through regulating HMGA1 transcriptional activity and that KIFC1 is a potential therapeutic target to enhance the paclitaxel sensitivity of HCC.
驱动蛋白在许多人类癌症的发生和发展中起着重要作用。驱动蛋白家族成员 C1(KIFC1)是驱动蛋白-14 家族的一员,其在肝细胞癌(HCC)发病机制中的功能和潜在机制尚未完全阐明。
本研究首先分析了 168 例 HCC 样本,以研究 KIFC1 表达与患者临床病理特征和预后的关系。在体内和体外研究了 KIFC1 在 HCC 细胞增殖和转移中的作用。通过 qRT-PCR、western blot、免疫共沉淀、染色质免疫沉淀(ChIP)和双荧光素酶报告基因检测研究了 KIFC1 的上游调控和下游靶标。
KIFC1 在 HCC 组织中高表达,与晚期和预后不良呈正相关。KIFC1 敲低抑制了 HCC 细胞在体外和体内的增殖和侵袭。此外,KIFC1 敲低减少了侵袭伪足的形成,降低了上皮-间充质转化(EMT)。高迁移率族蛋白 A1(HMGA1),一种结构转录因子,被鉴定为与 KIFC1 相互作用。HMGA1 可以结合 Stat3、MMP2 和 EMT 相关基因的启动子,促进基因转录。KIFC1 增强了 HMGA1 的转录活性,促进了 HCC 的增殖和侵袭。此外,KIFC1 被 TCF-4 激活,KIFC1 抑制增强了 HCC 细胞对紫杉醇的敏感性。
我们的研究结果表明,KIFC1 被 TCF-4 激活,作为一种癌基因,通过调节 HMGA1 的转录活性促进 HCC 的发病机制,并且 KIFC1 是增强 HCC 对紫杉醇敏感性的潜在治疗靶点。